http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2688181-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d584042a524740a406723fe1631e49e5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 |
| filingDate | 2019-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69ae6bf55645be11a74dc2b79b7ed89d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be358021f6a39745136094e1165ada09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ca7e730f8ca7f066ae367b0b520f5f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f6b4249a4deb81434adf0ec32d4e1f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_258386eca25ad0e226cdebbdcac1fa41 |
| publicationDate | 2019-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2688181-C1 |
| titleOfInvention | Method for prediction of response time to androgen deprivation therapy in patients with prostate cancer |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely to oncology, and can be used for prediction of response time to androgen-deprivation therapy (ADT) in patients with prostate cancer (PCa). Method involves examining biologically active molecules of tumour tissue with determining expression of AR, ERα, age of patient, level of testosterone and prostate-specific antigen (PSA) are also taken into account and values of discriminant functions Y1, Y2 are calculated by equations: Y1 = -33.37 + 1.0⋅X1 + 0.01⋅X2 + 0.01⋅X3 + 1.08⋅X4-0.0004 X5 (early recurrence of PCa with the effect of ADT for 12 months), Y2 = -59.27 + 1.75⋅X1 + 0.03⋅X2 + 0.23⋅X3-4.02⋅X4 + 0.007 X5 (delayed recurrence of PCa with the effect of ADT more than 12 months), where X1 is patient's age, years, X2 is AR expression in tumour, UE, X3 expression of ERα in tumour, UE, X4 - testosterone content in blood serum, nmol / l, X5 - content of prostate-specific antigen (PSA) in blood serum, ng/ml. If Y1> Y2 - the response to the ADT is predicted within the period of less than 12 months from the beginning of the treatment, and if Y1 <Y2 - more than 12 months from the beginning of the treatment. n EFFECT: using the invention enables predicting the length of recurrent disease with underlying ADT, predicting expected effects of the therapy and evaluating its effectiveness, and improving diagnostic accuracy and information value. n 1 cl, 4 tbl, 2 ex |
| priorityDate | 2019-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 131.